Varlitinib - Array BioPharma/ASLAN Pharmaceuticals
Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; VAR; Varlitinib tosylateLatest Information Update: 24 Jul 2024
Price :
$50 *
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; ASLAN Pharmaceuticals; National University Hospital (Singapore)
- Class Antineoplastics; Diamines; Oxazoles; Quinazolines; Small molecules; Thiazoles
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Biliary cancer; Cholangiocarcinoma; Gastric cancer; HER2 positive breast cancer; Liver cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 17 Jul 2024 Discontinued - Phase-I for Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO)
- 17 Jul 2024 Discontinued - Phase-I for Solid tumours (Combination therapy) in Singapore (PO)
- 17 Jul 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in Canada, USA (PO)